Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
55.18 USD | +2.56% | +2.18% | -12.30% |
04-18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
04-17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.30% | 4.57B | |
+24.79% | 42.68B | |
-3.27% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.58% | 24.94B | |
-20.02% | 18.96B | |
+29.25% | 12.3B | |
-2.77% | 11.95B | |
-1.48% | 11.55B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : Piper Sandler Adjusts Price Target on CRISPR Therapeutics to $180 From $107, Reiterates Overweight Rating